{"id":"NCT03510884","sponsor":"Sanofi","briefTitle":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-31","primaryCompletion":"2021-01-14","completion":"2022-08-05","firstPosted":"2018-04-27","resultsPosted":"2023-05-06","lastUpdate":"2023-05-06"},"enrollment":153,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolaemia"],"interventions":[{"type":"DRUG","name":"Alirocumab SAR236553 (REGN727)","otherNames":["Praluent"]},{"type":"DRUG","name":"Rosuvastatin","otherNames":[]},{"type":"DRUG","name":"Atorvastatin","otherNames":[]},{"type":"DRUG","name":"Simvastatin","otherNames":[]},{"type":"DRUG","name":"Pravastatin","otherNames":[]},{"type":"DRUG","name":"Lovastatin","otherNames":[]},{"type":"DRUG","name":"Fluvastatin","otherNames":[]},{"type":"DRUG","name":"Ezetimibe","otherNames":[]},{"type":"DRUG","name":"Cholestyramine","otherNames":[]},{"type":"DRUG","name":"Nicotinic acid","otherNames":[]},{"type":"DRUG","name":"Fenofibrate","otherNames":[]},{"type":"DRUG","name":"Omega-3 fatty acids","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo/Alirocumab Q2W","type":"EXPERIMENTAL"},{"label":"Alirocumab Q2W","type":"EXPERIMENTAL"},{"label":"Placebo/Alirocumab Q4W","type":"EXPERIMENTAL"},{"label":"Alirocumab Q4W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of alirocumab administered every 2 weeks (Q2W) and every 4 weeks (Q4W) versus placebo after 24 weeks of double-blind (DB) treatment on low-density lipoprotein cholesterol (LDL-C) levels in participants with heterozygous familial hypercholesterolemia (heFH) 8 to 17 years of age on optimal stable daily dose of statin therapy ± other lipid modifying therapies (LMTs) or a stable dose of non-statin LMTs in case of intolerance to statins.\n\nSecondary Objectives:\n\n* To evaluate the efficacy of alirocumab versus placebo on LDL-C levels.\n* To evaluate the effects of alirocumab versus placebo on other lipid parameters.\n* To evaluate the safety and tolerability of alirocumab in comparison with placebo.\n* To evaluate the efficacy, safety, and tolerability of alirocumab after open label treatment.\n* To evaluate the development of anti-alirocumab antibodies.","primaryOutcome":{"measure":"DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"DB Period: Placebo Q2W","deltaMin":9.7,"sd":4.3},{"arm":"DB Period: Alirocumab Q2W","deltaMin":-33.6,"sd":3.4},{"arm":"DB Period: Placebo Q4W","deltaMin":-4.4,"sd":3.7},{"arm":"DB Period: Alirocumab Q4W","deltaMin":-38.2,"sd":4}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":43,"countries":["United States","Argentina","Austria","Brazil","Bulgaria","Canada","Czechia","Denmark","Finland","France","Hungary","Italy","Lebanon","Mexico","Netherlands","Norway","Poland","Russia","Slovenia","South Africa","Spain","Sweden","Taiwan","Turkey (Türkiye)"]},"refs":{"pmids":["38315470"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Headache","Nasopharyngitis","Upper Respiratory Tract Infection","Injection Site Reaction","Covid-19"]}}